Overview

Evaluating the Impact of FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer

Status:
Not yet recruiting
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Ghent